Company intelligence / Profile preview

ThirtyFiveBio Limited

Milton (near Oxford), England, United Kingdom30fivebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ThirtyFiveBio has developed multiple unique families of first-in-class small-molecule GPR35 inhibitors. The lead program(s) are in preclinical development, including IND-enabling studies to support the initiation of first-in-human clinical trials. Preclinical data presented at AACR validated GPR35 as a novel cancer target and described potent, selective inhibitors. No clinical results reported yet.

Therapeutic areas: Gastroenterology
Modalities: small molecules (specifically small molecule antagonists/inhibitors)
Industry: Biotech

Drug pipeline

2 assets

TFB-00680

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

AbbVie Ventures – strategic investment/collaboration on IBD pipeline substrate potential

Beyond the preview

Go deeper on ThirtyFiveBio Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ThirtyFiveBio Limited.

Explore the full profile